Ursodeoxycholic Acid in Bariatric Surgery

Not Applicable

Completed

• Conditions: Non-alcoholic Fatty Liver Disease; Morbid Obesity
• Interventions: Drug: Ursodeoxycholic Acid (UDCA)

• Registration Number: NCT01548079
• Lead Sponsor: Sahlgrenska University Hospital, Sweden

Brief Summary

In an open-label trial, 20 otherwise healthy morbidly obese patients scheduled for bariatric surgery will be administered 20 mg/kg/day ursodeoxycholic acid for three weeks until the day before surgery. The maximum dose will be 3 g/day. Twenty other patients will serve as controls. Serum from days 1 and 21 will be analyzed for routine liver tests, bile acids, a complete lipid profile including FA and in addition for 7α-hydroxy-4-cholesten-3-one and fibroblast growth factor 19 (FGF-19), markers for bile acid synthesis its intestinal stimulation. For the evaluation of insulin resistance and possible pre-diabetes, plasma will be taken for the estimation of homeostasis model assessment (HOMA) index and oral glucose tolerance test (OGTT) will be performed at days 1 and 21. At surgery, a liver biopsy (0.5-1 g) and a white adipose tissue (WAT) specimen (1 cm2) will be taken and immediately frozen in liquid nitrogen for messenger ribonucleic acid (mRNA) and protein preparation for quantitative real-time polymerase chain reaction (RT-PCR) and Western analysis, respectively, histopathological Non-alcoholic fatty liver disease (NAFLD) grading, and measuring of hepatic and white adipose tissue (WAT) lipase activity. In all patients at randomization, abdominal ultrasound will be performed for the detection of NAFLD and gallstones and a blood sample will be taken for the analysis of polymorphisms of hepatic lipid synthesis, storage, fatty acid (FA) oxidation and export genes. Six month after operation, HOMA, OGTT and abdominal ultrasound will be repeated.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-10
• Primary Completion: 2009-11
• Study Completion: 2010-05
• Study First Submitted: 2012-02-22
• Study First Submitted QC: 2012-03-05
• Study First Posted: 2012-03-08
• Status Verified: 2013-12
• Last Update Submitted: 2013-12-02
• Last Update Posted: 2013-12-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• BMI ≥ 35 kg/m2
• Patients eligible to bariatric surgery
• Patients should have given their written consent to participate in this study

Exclusion Criteria

• Chronic liver disease other than NAFLD (viral hepatitis, autoimmune liver disease, hemochromatosis, homozygous alpha1-antitrypsin deficiency and Wilson disease)
• Partial ileal bypass
• Inflammatory bowel disease
• Uncontrolled diabetes mellitus (fasting blood glucose > 6.7 mmol/L), hypothyroidism or hyperthyroidism, or other significant endocrine disease.
• A subject who is euthyroid on a stable replacement dose of thyroid hormone is acceptable provided the TSH is within normal range.
• Other serious disease
• Known hypersensitivity to ursodeoxycholic acid
• Patients who will not comply with the protocol.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Ursodeoxycholic acid	Ursodeoxycholic Acid (UDCA)	Oral ursodeoxycholic acid 20 mg/kg/day in three weeks

Primary Outcome Measures

Name	Time	Method
Changes in regulators of lipid turnover	Baseline and 3 weeks	Trial objectives are to determine whether (i) Hepatic and/or visceral white adipose tissue (WAT) lipase activity determines fatty acid (FA) release/balance from lipid triglyceride (TG) droplets and FA-mediated lipotoxicity in NAFLD; differences in hepatic and/or WAT activity could explain individual susceptibility to pure NAFL versus NASH (ii) UDCA (20 mg/kg/day) improves insulin resistance in patients with NAFLD (iii) UDCA improves hepatobiliary transporter expression in NAFLD

Secondary Outcome Measures

Name	Time	Method
Changes in serum bile acids and lipids	Baseline and 3 weeks	* relative changes in hepatic basolateral transport proteins MRP3, MRP4, OATP, SLC21A1; * relative changes in m RNA expression levels of BAAT; CYP3A4, CYP7A1, CYP27, CYP8B1, UGT1A1, UGT2B4, UGT2B7, SULT2A1, HNF-4α, PXR/NR1I2, RXR/NR1B1; PERK, XBP-1, SREBP-1c; TNF-α, IL-6, IL-10, MCP-1, CxCl-1; * relative change in serum bile acids; * relative change in plasma 7α-hydroxy-4-cholesten-3-one and FGF-19; * relative changes in total cholesterol, LDL-C, HDL-C, Apo A1, Apo B, in Lp(A)